No Detail Found!

Pure Ductal Carcinoma in Situ: Clinicopathological Experience from a Single Tertiary Care Center

Author(s)
Nora Trabulsi Department of Surgery, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia
Mohammed Bahabri Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia
Hussain Alkhalifah Department of Surgery, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia
Rama Tayeb Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia
Ali Farsi Department of Surgery, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia
Alaa Shabkah Department of Surgery, International Medical Center, Jeddah, Saudi Arabia
Faris Alyamani Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia
Mohammed Aytah Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia
Salma Sait Department of Surgery, International Medical Center, Jeddah, Saudi Arabia
Marwan Al-Hajeili Department of Medicine, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia
Rana Ajabnoor Department of Pathology, Faculty of Medicine, King Abdulaziz University and King Abdulaziz University Hospital, Jeddah, Saudi Arabia
Zahir Fadel Division of Plastic Surgery, Department of Surgery, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia
Abstract
Objectives: In this study, we aimed to assess the clinicopathological characteristics and treatment outcomes of pure Ductal Carcinoma In Situ (DCIS) at King Abdulaziz University Hospital, in order to better understand its presentation, treatment approaches and rates of recurrence and progression. Methods: We conducted a retrospective analysis of 50 female patients diagnosed with pure DCIS from 2010 to 2020. Data on demographics, DCIS characteristics, treatment and outcomes were collected. Statistical analysis involved frequency distribution and descriptive statistics. Results: The median age at diagnosis for pure DCIS was 54 years. The median DCIS size was 16 mm and the most common morphological pattern was solid (26%). Grade II was the most frequent nuclear grade (40%), followed by grade III at 34% and grade I at 26%. Central (comedo) necrosis was present in 52% of cases. Regarding hormonal receptor status, 58% of cases were estrogen receptor positive and 44% progesterone receptor positive. Of the 23 cases tested for human epidermal growth factor receptor 2, 20% had positive results and 26% negative results. Negative surgical margins were achieved in 88% of cases. Adjuvant treatment included radiotherapy in 22% of patients and hormonal therapy in 34%. On follow-up, one recurrence and one progression to invasive ductal carcinoma were observed, with no DCIS-related mortality recorded. Conclusion: The findings show a low recurrence/progression rate for pure DCIS, consistent with global data indicating that many cases follow an indolent course. The study underscores the need for individualized treatment strategies to balance prevention of progression and avoidance of overtreatment.
Publication Details
Page(s) 36-42
DOI DOI not available
Published Journal: Journal of Pioneering Medical Sciences, Volume: 15, Issue: 1, Year: 2026

Request the full text from PASTIC

Keywords
ER/PR/HER2, Central (comedo) Necrosis, Pure DCIS, DCIS Size, morphological pattern
References
Sagara Y. .2015 .Survival benefit of breast surgery for lowgrade ductal carcinoma in situ: A population-based cohort study. ” JAMA Surgery, 150 : 739-745.
Grimm L.J. .2022 .Ductal carcinoma in situ: State-of-the-art review. ” Radiology, 302 : 246-255.
Ernster V.L. .2002 .Detection of ductal carcinoma in situ in women undergoing screening mammography. ” Journal of the National Cancer Institute, 94 : 1546-1554.
Kuerer H.M. . .DCIS margins and breast conservation: MD Anderson cancer center multidisciplinary practice guidelines and outcomes. ” Journal of Cancer, 8(2017) : 2653-2662.
Wadsten C. .2016 .A Validation of DCIS registration in a population-based breast cancer quality register and a study of treatment and prognosis for DCIS during 20 Years. Acta Oncologica, 55 : 1338-1343.
Bosaeed K.M. . .Cross-sectional descriptive study on the epidemiology of operated female breast tumor cases in a tertiary Hospital of Saudi Arabia. Saudi Surgical Journal, 6(2018) : 71-74.
Albasri A. .2014 .Histopathological features of breast cancer in Al-Madinah Region of Saudi Arabia. Saudi Medical Journal, 35 : 1489-1493.
Alnefaie S.M. .2024 .Incidence and characteristics of breast cancer in patients 40 years of age or younger. International Surgery Journal, 11 : 335-338.
Sopik V. .2018 .Impact of Microinvasion on breast cancer mortality in women with ductal carcinoma in Situ. Breast Cancer Research and Treatment, 167 : 787-795.
Giannakeas V. .2018 .A comparison of two models for breast cancer mortality for women with ductal Carcinoma in Situ. Breast Cancer Research and Treatment, 169 : 587-594.
Hanna W.M. .2019 .Ductal carcinoma in situ of the breast: an update for the pathologist. ” Modern Pathology, 32 : 896-915.
van Seijen M. .2019 .Ductal carcinoma in situ: To treat or not to treat, that is the question. British Journal of Cancer, 121 : 285-292.
Hagio K. .2021 .Genetic heterogeneity during breast cancer progression in young patients.” The Breast. , 60 : 206-213.
van der Borden C.L. . .Avoiding overtreatment of ductal carcinoma in situ. ” Trends in Cancer, 5(2019) : 391-393.
Casasent A.K. .2017 .Genome Evolution in ductal carcinoma in situ: invasion of the clones. ” Journal of Pathology, 241 : 208-218.
Sakr R.A. .2014 .PI3K Pathway activation in high-grade ductal carcinoma in situ. ” Clinical Cancer Research, 20 : 2326-2337.
Pareja F. .2020 .Whole-exome sequencing analysis of the progression from non-low-grade ductal carcinoma in situ to invasive ductal carcinoma. ” Clinical Cancer Research, 26 : 3682-3693.
Gibson S.V. . .Everybody needs good neighbours: the progressive DCIS microenvironment. ” Trends in Cancer, 9(2023) : 326-338.
Ponti A. .2019 .Low-grade screen-detected ductal carcinoma in situ progresses more slowly than high-grade lesions. ” Breast Cancer Research and Treatment, 177 : 761-765.
Zhao M.R. .2023 .Feasibility analysis of MRI-based radiomics for preoperative prediction of nuclear grading of DCIS.” Gland Surgery. , 12 : 1209-1223.
Cutuli B. .2020 .Ductal Carcinoma in situ: A French national survey. ” Clinical Breast Cancer, 20 : e164-e172.
Alaeikhanehshir S. .2024 .Effects of contemporary treatment of DCIS on the risk of ipsilateral invasive breast cancer. ” Breast Cancer Research and Treatment, 204 : 61-68.
Shaaban A.M. .2021 .Pathological features of 11,337 patients with primary DCIS. British Journal of Cancer, 124 : 1009-1017.
Goh C.W. .2019 .. “IDC/DCIS versus Pure IDC.” Journal of Cancer Research and Clinical Oncology, 145 : 1877-1886.
Song G.,Y. Zhang. G. . .Breast DCIS with microinvasion. ” Chronic Diseases and Translational Medicine, 9(2023) : 5-13.
Doebar S.C. .2016 .Extent of DCIS according to breast cancer subtypes. ” Breast Cancer Research and Treatment, 158 : 179-187.
Al-Ameer A.Y. . .Sentinel lymph node biopsy in clinically detected DCIS. World Journal of Clinical Oncology, 7(2016) : 258-264.
Groen E.J. .2020 .Prognostic value of histopathological DCIS Features. Breast Cancer Research and Treatment, 183 : 759-770.
Pinder S.E. .2010 .A New pathological system for grading DCIS. British Journal of Cancer, 103 : 94-100.
Badve S.S.,Gökmen-Polar Y. .2019 .. Ductal carcinoma in situ of breast: Update 2019.” Pathology, 51 : 563-569.
Wang J. . .Progression from DCIS to invasive breast cancer. ” Signal Transduction and Targeted Therapy, 9(2024) : 83.
Schandiz H. .2023 .Subtypes of high-grade DCIS. Breast Cancer Research and Treatment, 201 : 329-338.
Howard-McNatt M. .2021 .Impact of cavity shave margins in DCIS.” Journal of the American College of Surgeons. , 232 : 373-378.
Kunkiel M.,A M. .2021 .. Van Nuys prognostic index in DCIS.” Scientific Reports, 11 : 22645.
Sigal-Zafrani B. .2004 .Histological margin assessment for DCIS.” Modern Pathology. , 17 : 81-88.
Hwang E.S. .2024 .Active monitoring for low-risk DCIS: The COMET Trial. ” JAMA, 333 : 972-980.
Elshof L.E. .2015 .. The LORD Study.” European Journal of Cancer, 51 : 1497-1510.
Francis A. .2015 .. The LORIS Trial.” European Journal of Cancer, 51 : 2296-2303.
Kanbayashi C. .2019 .International collaboration of active surveillance trials for low-risk DCIS. ” Journal of Clinical Oncology, 37(suppl) : .
0

Citations

0

Downloads

17

Views